Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002
In connection with the quarterly report of Cocrystal Pharma, Inc.
(the “Company”) on Form 10-Q for the quarter ended
September 30, 2016, as filed with the Securities and Exchange
Commission on the date hereof, I, Gary Wilcox, certify, pursuant to
18 U.S.C. Sec.1350, as adopted pursuant to Sec.906 of the
Sarbanes-Oxley Act of 2002, that to my knowledge:
1. The
quarterly report fully complies with the requirements of section
13(a) or 15(d) of the Securities Exchange Act of 1934
and
2. The
information contained in the quarterly report fairly presents, in
all material respects, the financial condition and results of
operations of the Company.
/s/
Gary Wilcox
|
Gary Wilcox
Interim Chief Executive Officer
(Principal Executive Officer)
|
Dated: November 9, 2016
In connection with the quarterly report of Cocrystal Pharma, Inc.
(the “Company”) on Form 10-Q for the quarter ended
September 30, 2016, as filed with the Securities and Exchange
Commission on the date hereof, I, Curtis Dale, certify, pursuant to
18 U.S.C. Sec.1350, as adopted pursuant to Sec.906 of the
Sarbanes-Oxley Act of 2002, that to my knowledge:
1. The
quarterly report fully complies with the requirements of section
13(a) or 15(d) of the Securities Exchange Act of 1934
and
2. The
information contained in the quarterly report fairly presents, in
all material respects, the financial condition and results of
operations of the Company.
/s/Curtis Dale
Curtis Dale
Interim Chief Financial Officer
(Principal Financial Officer)
Dated: November 9, 2016